For pts with TP53 and EGFR-positive mutations in EC-3, 13/16 (81.3%) PRs were observed, and the median progression-free survival (range) was 16.39 (8.11-NR) months. Preliminary biomarker data from pts in EC-2 suggested that high BCL-xL expression was associated with antitumor efficacy...Based on these findings, pelcitoclax plus osimertinib is of potential clinical interest to improve outcomes of pts with TP53- and EGFR-mutant NSCLC.